The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology

Autor: Loupy, Alexandre, Haas, Mark, Solez, Kim, Racusen, L., Glotz, Denis, Serón Micas, Daniel, Nankivell, B. J., Colvin, Robert, Afrouzian, Marjan, Akalin, Enver, Alachkar, Nada, Bagnasco, Serena, Becker, Jan U, Cornell, Lynn, Drachenberg, C., Dragun, Duska, de Kort, H., Gibson, I. W., Kraus, E. S., Lefaucheur, Carmen, Legendre, C., Liapis, H., Muthukumar, T., Nickeleit, V., Orandi, B., Park, W., Rabant, Marion, Randhawa, P., Reed, E. F., Roufosse, C., Seshan, S. V., Sis, B., Singh, H. K., Schinstock, C., Tambur, Anat R., Zeevi, Adriana, Mengel, Michael, Universitat Autònoma de Barcelona
Přispěvatelé: Roche Organ Transplant Research Foundation
Rok vydání: 2017
Předmět:
Graft Rejection
Research Report
Pathology
RENAL-ALLOGRAFT REJECTION
translational research/science
subclinical [Rejection]
TRANSPLANTATION BIFQUIT REPRODUCIBILITY
COMPLEMENT-BINDING
rejection: T cell mediated (TCMR)
030232 urology & nephrology
kidney transplantation/nephrology
Meeting Report
030230 surgery
Medical and Health Sciences
Meeting Reports
0302 clinical medicine
Isoantibodies
DONOR-SPECIFIC ANTIBODIES
Immunology and Allergy
Molecular diagnostic techniques
organ transplantation in general
Pharmacology (medical)
science
Kidney transplantation
screening and diagnosis
MICROARRAY DIAGNOSIS
Kidney transplantation/nephrology
Molecular pathology
Pathology/histopathology
11 Medical And Health Sciences
T cell mediated [Rejection]
practice
rejection: subclinical
3. Good health
Detection
Organ transplantation in general
Allograft rejection
BIOPSIES
histopathology
Clinical research/practice
Translational research/science
rejection
Life Sciences & Biomedicine
pathology/histopathology
antibody-mediated [Rejection]
medicine.medical_specialty
QUALITY-ASSURANCE
Renal and urogenital
nephrology
kidney transplantation
clinical research/practice
ANTIBODY-MEDIATED REJECTION
Rejection
03 medical and health sciences
Clinical Research
Complement C4b
medicine
Humans
Intensive care medicine
GRAFT FAILURE
Arteritis
Transplantation
Science & Technology
business.industry
Gene sets
Organ Transplantation
medicine.disease
Peptide Fragments
4.1 Discovery and preclinical testing of markers and technologies
Clinical trial
clinical research
translational research
rejection: antibody‐mediated (ABMR)
Cardiovascular and Metabolic Diseases
rejection: antibody-mediated (ABMR)
NON-HLA ANTIBODIES
Surgery
pathology
business
Reporting system
Zdroj: American Journal of Transplantation, 17(1), 28-41
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol 17, iss 1
American Journal of Transplantation
ISSN: 1600-6135
DOI: 10.1111/ajt.14107
Popis: The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d‐negative antibody‐mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor‐specific antibody tests (anti‐HLA and non‐HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i‐IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell–mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus‐based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next‐generation clinical trials.
In this article, the Banff consortium presents the most updated version of the kidney, pancreas, and VCA transplant rejection classification and prospects for implementing intragraft molecular assessment. See the companion report on page 42.
Databáze: OpenAIRE
Externí odkaz: